162 related articles for article (PubMed ID: 17456742)
1. The 2.0 A crystal structure of the ERalpha ligand-binding domain complexed with lasofoxifene.
Vajdos FF; Hoth LR; Geoghegan KF; Simons SP; LeMotte PK; Danley DE; Ammirati MJ; Pandit J
Protein Sci; 2007 May; 16(5):897-905. PubMed ID: 17456742
[TBL] [Abstract][Full Text] [Related]
2. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
[TBL] [Abstract][Full Text] [Related]
3. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in
Hosfield DJ; Weber S; Li NS; Sauvage M; Joiner CF; Hancock GR; Sullivan EA; Ndukwe E; Han R; Cush S; Lainé M; Mader SC; Greene GL; Fanning SW
Elife; 2022 May; 11():. PubMed ID: 35575456
[TBL] [Abstract][Full Text] [Related]
4. Selective estrogen receptor modulator (SERM) lasofoxifene forms reactive quinones similar to estradiol.
Michalsen BT; Gherezghiher TB; Choi J; Chandrasena RE; Qin Z; Thatcher GR; Bolton JL
Chem Res Toxicol; 2012 Jul; 25(7):1472-83. PubMed ID: 22642258
[TBL] [Abstract][Full Text] [Related]
5. In Vitro and In Silico Analyses of the Inhibition of Human Aldehyde Oxidase by Bazedoxifene, Lasofoxifene, and Structural Analogues.
Chen S; Austin-Muttitt K; Zhang LH; Mullins JGL; Lau AJ
J Pharmacol Exp Ther; 2019 Oct; 371(1):75-86. PubMed ID: 31289113
[TBL] [Abstract][Full Text] [Related]
6. CB2 cannabinoid receptor is a novel target for third-generation selective estrogen receptor modulators bazedoxifene and lasofoxifene.
Kumar P; Song ZH
Biochem Biophys Res Commun; 2014 Jan; 443(1):144-9. PubMed ID: 24275139
[TBL] [Abstract][Full Text] [Related]
7. Lasofoxifene: CP 336156, CP-336156.
Drugs R D; 2005; 6(1):56-60. PubMed ID: 15801869
[TBL] [Abstract][Full Text] [Related]
8. Chemical and biochemical issues related to X-ray crystallography of the ligand-binding domain of estrogen receptor alpha.
Goldstein SW; Bordner J; Hoth LR; Geoghegan KF
Bioconjug Chem; 2001; 12(3):406-13. PubMed ID: 11353539
[TBL] [Abstract][Full Text] [Related]
9. Transactivation Function-1-Mediated Partial Agonist Activity of Selective Estrogen Receptor Modulator Requires Homo-Dimerization of the Estrogen Receptor α Ligand Binding Domain.
Arao Y; Korach KS
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31366023
[TBL] [Abstract][Full Text] [Related]
10. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T; Ke HZ; Simmons H; Thompson D
Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
[TBL] [Abstract][Full Text] [Related]
11. Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in female rats.
Terry KK; Cappon GD; Hurtt ME; Tassinari MS; Gupta U
Birth Defects Res B Dev Reprod Toxicol; 2004 Jun; 71(3):150-60. PubMed ID: 15282736
[TBL] [Abstract][Full Text] [Related]
12. Structural insights into Resveratrol's antagonist and partial agonist actions on estrogen receptor alpha.
Chakraborty S; Levenson AS; Biswas PK
BMC Struct Biol; 2013 Oct; 13():27. PubMed ID: 24160181
[TBL] [Abstract][Full Text] [Related]
13. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.
Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD
Menopause; 2006; 13(4):609-20. PubMed ID: 16837883
[TBL] [Abstract][Full Text] [Related]
14. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis.
Gennari L
Drugs Today (Barc); 2006 Jun; 42(6):355-67. PubMed ID: 16845439
[TBL] [Abstract][Full Text] [Related]
15. Conformational dynamics of the estrogen receptor alpha: molecular dynamics simulations of the influence of binding site structure on protein dynamics.
Celik L; Lund JD; Schiøtt B
Biochemistry; 2007 Feb; 46(7):1743-58. PubMed ID: 17249692
[TBL] [Abstract][Full Text] [Related]
16. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland.
Peano BJ; Crabtree JS; Komm BS; Winneker RC; Harris HA
Endocrinology; 2009 Apr; 150(4):1897-903. PubMed ID: 19022889
[TBL] [Abstract][Full Text] [Related]
17. Pre- and postnatal development studies of lasofoxifene, a selective estrogen receptor modulator (SERM), in Sprague-Dawley rats.
Weisenburger WP; Hagler AR; Tassinari MS
Birth Defects Res B Dev Reprod Toxicol; 2004 Jun; 71(3):171-84. PubMed ID: 15282738
[TBL] [Abstract][Full Text] [Related]
18. Transactivation Function-2 of Estrogen Receptor α Contains Transactivation Function-1-regulating Element.
Arao Y; Coons LA; Zuercher WJ; Korach KS
J Biol Chem; 2015 Jul; 290(28):17611-27. PubMed ID: 26028650
[TBL] [Abstract][Full Text] [Related]
19. Enzyme-catalyzed asymmetric deacylation for the preparation of lasofoxifene (CP-336156), a selective estrogen receptor modulator.
Yang X; Reinhold AR; Rosati RL; Liu KK
Org Lett; 2000 Dec; 2(25):4025-7. PubMed ID: 11112634
[TBL] [Abstract][Full Text] [Related]
20. Ligand-selective interdomain conformations of estrogen receptor-alpha.
Padron A; Li L; Kofoed EM; Schaufele F
Mol Endocrinol; 2007 Jan; 21(1):49-61. PubMed ID: 17008385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
